Literature DB >> 22396312

Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture.

Shuangling Chen1, Lorenzo Principessa, John T Isaacs.   

Abstract

BACKGROUND: Recent experimental studies suggest that hierarchical expansion from a minor population of cancer cells with an unlimited self-renewal capacity, termed cancer initiating cells (CICs), drives both lethality and heterogeneity of prostate cancer. Human prostate CICs have been established from only two primary prostate cancer patients, with the remaining established CIC lines being derived from metastatic sites from <10 patients. This suggests that the established CIC lines are significant "outliers" and may not be representative of the prostate CICs seen clinically. Thus, there is an urgent need to develop new approaches to achieve the "routine" establishment of CIC containing lines, particularly derived from primary prostate cancers.
METHODS: In the present studies, we confirmed that in serum free, high Ca(2+) (i.e., DMEN: F12) growth factor defined (GFD) media plus androgen, a large (n = 10) series of established human prostate cancer cell lines derived from both localized and metastatic sites characteristically self-associate in suspension and grow as unattached spheroids, termed prostaspheres which contain CICs based upon their self-renewal in vitro and tumorigenicity in vivo.
RESULTS: Unfortunately, however, while dissociated single cells from human primary prostate cancer tissues are viable, contain CICs as documented by their ability to take and proliferate as xenografts, and produce prostaspheres when plated with serum free, high Ca(2+) /GFD-media plus androgen onto standard tissue culture flask, these prostasphere do not contain CICs.
CONCLUSION: The development of reproducibly methods to culture CICs isolated directly from localized cancers is still an urgent unmeet need of the prostate cancer research community.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22396312      PMCID: PMC3578386          DOI: 10.1002/pros.22503

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

1.  Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

Authors:  Chen Wei; Wang Guomin; Liu Yujun; Qian Ruizhe
Journal:  Cancer Biol Ther       Date:  2007-02-08       Impact factor: 4.742

2.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 3.  Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.

Authors:  Donald J Vander Griend; Ivan V Litvinov; John T Isaacs
Journal:  Cell Cycle       Date:  2007-03-21       Impact factor: 4.534

4.  Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death.

Authors:  Mathew J Edick; Lia Tesfay; Laura E Lamb; Beatrice S Knudsen; Cindy K Miranti
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

Review 6.  Prostate stem cells and benign prostatic hyperplasia.

Authors:  John T Isaacs
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

7.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

8.  Characterization of PacMetUT1, a recently isolated human prostate cancer cell line.

Authors:  D A Troyer; Y Tang; R Bedolla; S G Adhvaryu; I M Thompson; S Abboud-Werner; L-Z Sun; W E Friedrichs; L A deGraffenried
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

9.  Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.

Authors:  Guangyu Gu; Jialing Yuan; Marcia Wills; Susan Kasper
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

10.  CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Authors:  E M Hurt; B T Kawasaki; G J Klarmann; S B Thomas; W L Farrar
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

View more
  8 in total

1.  Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Authors:  Mindy Kim Graham; Lorenzo Principessa; Lizamma Antony; Alan K Meeker; John T Isaacs
Journal:  Prostate       Date:  2016-11-08       Impact factor: 4.104

2.  Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Authors:  Sarah R Young; Matthias Saar; Jennifer Santos; Holly M Nguyen; Robert L Vessella; Donna M Peehl
Journal:  Prostate       Date:  2013-06-06       Impact factor: 4.104

3.  Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples.

Authors:  Shunqi Wang; Shengsong Huang; Xin Zhao; Qimin Zhang; Min Wu; Feng Sun; Gang Han; Denglong Wu
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 4.  Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.

Authors:  Sander Frank; Peter Nelson; Valeri Vasioukhin
Journal:  F1000Res       Date:  2018-08-02

5.  Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16.

Authors:  Guolong Liao; Jiani Tang; Di Wang; Haoru Zuo; Qi Zhang; Ying Liu; Haiyun Xiong
Journal:  World J Surg Oncol       Date:  2020-05-01       Impact factor: 2.754

Review 6.  Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells' Role in Tumor Progression.

Authors:  Shivani Baisiwala; Shreya Budhiraja; Chirag Goel; Khizar R Nandoliya; Miranda R Saathoff; Atique U Ahmed
Journal:  Stem Cell Rev Rep       Date:  2021-07-09       Impact factor: 6.692

7.  Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.

Authors:  W Nathaniel Brennen; Shuangling Chen; Samuel R Denmeade; John T Isaacs
Journal:  Oncotarget       Date:  2013-01

8.  Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.

Authors:  Kenneth J Pienta; Guneet Walia; Jonathan W Simons; Howard R Soule
Journal:  Prostate       Date:  2014-02       Impact factor: 4.104

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.